Abstract
Current understanding of lipid genetics has come mainly from studies in European-ancestry populations; limited effort has focused on Polynesian populations, whose unique population history and high prevalence of dyslipidemia may provide insight into the biological foundations of variation in lipid levels. Here we performed an association study to fine map a suggestive association on 5q35 with high-density lipoprotein cholesterol (HDL-C) seen in Micronesian and Polynesian populations. Fine-mapping analyses in a cohort of 2,851 Samoan adults highlighted an association between a stop-gain variant (rs200884524; c.652C>T, p.R218*; posterior probability = 0.9987) in BTNL9 and both lower HDL-C and greater triglycerides (TG). Meta-analysis across this and several other cohorts of Polynesian ancestry from Samoa, American Samoa, and Aotearoa New Zealand confirmed the presence of this association (β.HDL-C = -1.60 mg/dL, p.HDL-C = 7.63 x 10-10; β.TG = 12.00 mg/dL, p.TG = 3.82 x 10-7). While this variant appears to be Polynesian-specific, there is also evidence of association from other multi-ancestry analyses in this region. This work provides evidence of a previously unexplored contributor to the genetic architecture of lipid levels and underscores the importance of genetic analyses in understudied populations
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Institute of Health grants R01HL093093 (STM), R01HL133040 (RLM), R01AG09375 (STM), R01HL52611 (MI Kamboh), R01DK59642 (STM), R01DK55406 (RD), and by the New Zealand Health Research Council. Genotyping was performed in the Core Genotyping Laboratory at the University of Cincinnati, funded by National Institutes of Health grant P30ES006096 (SM Ho).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by institutional review boards of Brown University and the American Samoa Department of Health, the Health Research Committee of the Samoa Ministry of Health, the New Zealand Multi-Region Ethics Committee, and the Northern Y Region Health Research Ethics Committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The discovery cohort data used for this study are available through dbGaP (accession numbers: phs000914.v1.p1 and phs000972.v5.p1). The Samoan/American Samoan and Aotearoa New Zealand replication cohorts' data have not been deposited in a public repository because participants did not give consent for data sharing. Code used for data analysis will be made available upon request.
